Shots:

• Regenxbio to receive up front- development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio's NAV AAV9 vector to develop & commercialize gene therapies for Friedreich's ataxia
• The focus of the agreement is to strengthen Regenxbio’s intellectual property portfolio and the potential of NAV AAV9 to treat systemic and CNS manifestations of movement disorders
• Regenxbio’s NAV technology platform is an AAV gene delivery platform consisting of 100+ AAV vectors including AAV7- AAV8- AAV9 and AAVrh10 applicable for multiple therapeutic areas

Click here to­ read full press release/ article | Ref: Regenxbio | Image: Pharmaceutical Technology